Boule Diagnostics

Year-end report
Q4 2022

Financial Highlights

NET SALES, MSEK
149.2
GROSS MARGIN
44.7
%
OPERATING PROFIT, MSEK
10
OPERATIONAL CASH FLOW, MSEK
13.3
DSC5200A (1)

Strengthened financial position and positive growth for OEM business

I am pleased that we were able to deliver milestones during the fourth quarter, both in the development of the new product platform and in our quality work.

Sales for the fourth quarter increased by six percent compared to the previous year, totaling SEK 149 million. Organically, sales fell by eight percent. Sales of consumables continue to take a positive direction. The use of instruments is back to pre-pandemic levels. We had lower sales of 3-part instruments, which is partly explained by a shift from 3-part to 5-part instruments. However, I believe that 3-part instruments will continue to be used in the decentralized market and will make up the majority of the installed base for many years to come.

Net sales by region

Net sales by product

Near-patient diagnostics

Complete Blood Count (CBC) is the most common test for in vitro diagnostics. The decentralized and patient-related hematology segment has an estimated market value of just over SEK 6 billion, while the corresponding segment for the veterinary market is valued at approximately SEK 2.6 billion

Map En

100
+

Countries

SEK
9
BILLION

Human and veterinary market

140
MILLION

Tests per year

ABOUT BOULE DIAGNOSTICS

Boule Diagnostics AB is a global diagnostics company specializing in near-patient, decentralized blood diagnostics and one of the few companies in the global diagnostics market that conducts its own development, manufacturing and marketing of instruments and consumables for blood diagnostics. The Company primarily serves hospitals, clinics, laboratories and other diagnostics companies.